Hiroaki Ito
About Hiroaki Ito
Hiroaki Ito is the Senior Manager, Oncology Medical Lead in GU/Melanoma at Bristol Myers Squibb in Shinjuku, Tokyo, with extensive experience in immunology and oncology research.
Company
Hiroaki Ito currently works at Bristol Myers Squibb as Senior Manager, Oncology Medical Lead in GU/Melanoma. He has been with the company since 2015, initially working as a Medical Science Liaison for six years in Osaka, Japan. Hiroaki Ito's contributions have been significant in the field of immuno-oncology, particularly in the development of GU cancer treatments.
Title
Hiroaki Ito holds the position of Senior Manager, Oncology Medical Lead in GU/Melanoma at Bristol Myers Squibb. In this role, he leads the medical strategies and developments for genitourinary cancers and melanoma. His leadership extends to mentoring junior researchers and collaborating with cross-functional teams to advance new immunotherapy protocols.
Education and Expertise
Hiroaki Ito studied at 東京大学, where he earned a Ph.D. in Immunology from 2003 to 2006 and an M.S. in Immunology from 2001 to 2003. Prior to this, he studied Biotechnology at Tokyo University of Science, achieving a B.S. from 1997 to 2001. His academic background is further strengthened by his extensive research and multiple publications in peer-reviewed journals on immuno-oncology.
Professional Background
Hiroaki Ito's professional background includes serving as an Assistant Professor in the Division of Host-Parasite Interaction at The University of Tokyo from 2012 to 2015. He also worked as an Affiliate Instructor at the University of Washington from 2010 to 2012. His earlier roles include being a Postdoctoral Fellow at Benaroya Research Institute at Virginia Mason from 2008 to 2012 and at the University of Tokyo from 2006 to 2008.
Achievements
Hiroaki Ito has been recognized for his contributions to the development of genitourinary cancer treatments. He has published multiple research papers on immuno-oncology in peer-reviewed journals and presented his findings on melanoma treatment at international oncology conferences. His collaborative efforts have been pivotal in developing new immunotherapy protocols at Bristol Myers Squibb.